These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Binding of Ixr1, a yeast HMG-domain protein, to cisplatin-DNA adducts in vitro and in vivo. McA'Nulty MM, Whitehead JP, Lippard SJ. Biochemistry; 1996 May 14; 35(19):6089-99. PubMed ID: 8634251 [Abstract] [Full Text] [Related]
24. Modification of natural, double-helical DNA by antitumor cis- and trans-[Cl(2)(Me(2)SO(4))(4)Ru] in cell-free media. Nováková O, Hofr C, Brabec V. Biochem Pharmacol; 2000 Dec 15; 60(12):1761-71. PubMed ID: 11108791 [Abstract] [Full Text] [Related]
29. DNA sequence context and protein composition modulate HMG-domain protein recognition of cisplatin-modified DNA. Dunham SU, Lippard SJ. Biochemistry; 1997 Sep 23; 36(38):11428-36. PubMed ID: 9298962 [Abstract] [Full Text] [Related]
30. Repair of cisplatin--DNA adducts by the mammalian excision nuclease. Zamble DB, Mu D, Reardon JT, Sancar A, Lippard SJ. Biochemistry; 1996 Aug 06; 35(31):10004-13. PubMed ID: 8756462 [Abstract] [Full Text] [Related]
31. A single HMG domain in high-mobility group 1 protein binds to DNAs as small as 20 base pairs containing the major cisplatin adduct. Chow CS, Barnes CM, Lippard SJ. Biochemistry; 1995 Mar 07; 34(9):2956-64. PubMed ID: 7893709 [Abstract] [Full Text] [Related]
32. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Huang JC, Zamble DB, Reardon JT, Lippard SJ, Sancar A. Proc Natl Acad Sci U S A; 1994 Oct 25; 91(22):10394-8. PubMed ID: 7937961 [Abstract] [Full Text] [Related]
35. Unique properties of DNA interstrand cross-links of antitumor oxaliplatin and the effect of chirality of the carrier ligand. Kasparkova J, Vojtiskova M, Natile G, Brabec V. Chemistry; 2008 Oct 25; 14(4):1330-41. PubMed ID: 18022972 [Abstract] [Full Text] [Related]
36. Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor). Treiber DK, Zhai X, Jantzen HM, Essigmann JM. Proc Natl Acad Sci U S A; 1994 Jun 07; 91(12):5672-6. PubMed ID: 8202546 [Abstract] [Full Text] [Related]
37. Intrastrand cross-links are not formed in the reaction between transplatin and native DNA: relation with the clinical inefficiency of transplatin. Boudvillain M, Dalbiès R, Aussourd C, Leng M. Nucleic Acids Res; 1995 Jul 11; 23(13):2381-8. PubMed ID: 7630715 [Abstract] [Full Text] [Related]
38. The stability of DNA intrastrand cross-links of antitumor transplatin derivative containing non-bulky methylamine ligands. Frybortova M, Novakova O, Brabec V. J Biol Inorg Chem; 2014 Oct 11; 19(7):1203-8. PubMed ID: 24986778 [Abstract] [Full Text] [Related]
40. Effects of a piperidine ligand on DNA modification by antitumor cisplatin analogues. Kasparkova J, Novakova O, Najajreh Y, Gibson D, Perez JM, Brabec V. Chem Res Toxicol; 2003 Nov 11; 16(11):1424-32. PubMed ID: 14615968 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]